Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNFTF Genfit

Market Closed 12-12 16:00:00 EST Delay

{"stockData":{"symbol":"GNFTF","market":"US","secType":"STK","nameCN":"Genfit","latestPrice":4.14,"timestamp":1765573200000,"preClose":4.14,"halted":0,"volume":0,"delay":15,"floatShares":41846888,"shares":49758671,"eps":-0.642605,"marketStatus":"Market Closed","change":0,"latestTime":"12-12 16:00:00 EST Delay","open":4.14,"high":4.14,"low":4.14,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.642605,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":4.14,"volumeRatio":0.14563082759960494},"requestUrl":"/m/hq/s/GNFTF","defaultTab":"news","newsList":[{"id":"2585650159","title":"GENFIT 9-Months 2025 Revenue €39.2 Million; Says As of September 30, 2025, The Company's Cash And Cash Equivalents Amounted To €119.0 Million Compared With €107.5 Million As Of June 30, 2025, And €81.8 Million As Of December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2585650159","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585650159?lang=en_us&edition=fundamental","pubTime":"2025-11-21 01:13","pubTimestamp":1763658827,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48982509/genfit-9-months-2025-revenue-39-2-million-says-as-of-september-30-2025-the-companys-cash-and-cash-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFTF"],"gpt_icon":0},{"id":"2582587462","title":"GENFIT Unveils Promising Preclinical Data for ACLF Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587462","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587462?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:28","pubTimestamp":1762781332,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) just unveiled an update. On November 10, 2025, GENFIT presented promising preclinical data for its investigational drug G1090...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-unveils-promising-preclinical-data-for-aclf-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-unveils-promising-preclinical-data-for-aclf-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2582874545","title":"GENFIT Collaborates with EVerZom to Advance Exosome-Based Therapy for ACLF","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874545","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874545?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:28","pubTimestamp":1762781317,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) just unveiled an update. On November 10, 2025, GENFIT announced a research collaboration with EVerZom to advance exosome-base...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-collaborates-with-everzom-to-advance-exosome-based-therapy-for-aclf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-collaborates-with-everzom-to-advance-exosome-based-therapy-for-aclf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNFTF"],"gpt_icon":0},{"id":"2579031801","title":"Genfit announces intention to voluntarily delist ADSs from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2579031801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579031801?lang=en_us&edition=fundamental","pubTime":"2025-10-31 05:10","pubTimestamp":1761858657,"startTime":"0","endTime":"0","summary":"Genfit (GNFT) announced it has given formal notice to the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genfit-announces-intention-to-voluntarily-delist-adss-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genfit-announces-intention-to-voluntarily-delist-adss-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSYW.SI","NQmain","SQQQ","MNQmain","USAW.SI","TQQQ","BK4139","USJW.SI","PSQ","QLD","GNFTF","QID","NVIW.SI","GNFT",".IXIC"],"gpt_icon":0},{"id":"2579918974","title":"GENFIT Showcases ACLF Pipeline Advances at AASLD Liver Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579918974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579918974?lang=en_us&edition=fundamental","pubTime":"2025-10-29 05:27","pubTimestamp":1761686857,"startTime":"0","endTime":"0","summary":"An update from Genfit SA ( ($GNFT) ) is now available. On October 28, 2025, GENFIT announced its participation in the upcoming AASLD The Liver Meet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-showcases-aclf-pipeline-advances-at-aasld-liver-meeting-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-showcases-aclf-pipeline-advances-at-aasld-liver-meeting-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNFTF"],"gpt_icon":0},{"id":"2569703265","title":"Genfit Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2569703265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569703265?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:10","pubTimestamp":1758712200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNFT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 24, 2025 07:10 ET (11:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFTF"],"gpt_icon":0},{"id":"2569877043","title":"Genfit price target lowered to $7 from $9 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2569877043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569877043?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:10","pubTimestamp":1758708612,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Genfit (GNFT) to $7 from $9 and keeps a Buy rating on the shares. The company last week announce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genfit-price-target-lowered-to-7-from-9-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genfit-price-target-lowered-to-7-from-9-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2569723127","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Genfit (OtherGNFTF), Sanofi (OtherSNYNF) and Roche Holding AG (OtherRHHVF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569723127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569723127?lang=en_us&edition=fundamental","pubTime":"2025-09-24 09:40","pubTimestamp":1758678004,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Genfit (GNFTF – Research Report), Sanofi (SNYNF – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-genfit-othergnftf-sanofi-othersnynf-and-roche-holding-ag-otherrhhvf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-genfit-othergnftf-sanofi-othersnynf-and-roche-holding-ag-otherrhhvf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4581","BK4139","HCSG","GNFTF","LABU","XBI","BK4588","BK4585","BK4007","XLV","BK4137","BK4210","AG"],"gpt_icon":0},{"id":"2569658757","title":"Genfit’s 2025 Mid-Year Financial and Strategic Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2569658757","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569658757?lang=en_us&edition=fundamental","pubTime":"2025-09-23 11:52","pubTimestamp":1758599576,"startTime":"0","endTime":"0","summary":"Genfit ( ($GNFT) ) has released its Q2 earnings. Here is a breakdown of the information Genfit presented to its investors. Genfit is a French bioph...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfits-2025-mid-year-financial-and-strategic-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfits-2025-mid-year-financial-and-strategic-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2569821765","title":"Genfit SA Reports Revenue Decline and Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2569821765","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569821765?lang=en_us&edition=fundamental","pubTime":"2025-09-23 11:52","pubTimestamp":1758599559,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFTF) ) has released its Q2 earnings. Here is a breakdown of the information Genfit SA presented to its investors. Genfit SA is a Fr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-sa-reports-revenue-decline-and-net-loss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-sa-reports-revenue-decline-and-net-loss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2569730551","title":"Genfit H1 EPS $(0.23) Down From $0.57 YoY, Sales $40.443M Down From $65.887M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2569730551","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569730551?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:11","pubTimestamp":1758571917,"startTime":"0","endTime":"0","summary":"Genfit (NASDAQ:GNFT) reported quarterly losses of $(0.23) per share. This is a 140.35 percent decrease over earnings of $0.57 per share from the same period last year.  The company reported $40.443 million in sales this","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47806266/genfit-h1-eps-0-23-down-from-0-57-yoy-sales-40-443m-down-from-65-887m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genfit H1 EPS $(0.23) Down From $0.57 YoY, Sales $40.443M Down From $65.887M YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFTF"],"gpt_icon":0},{"id":"2568299026","title":"Genfit Discontinues VS-01 in ACLF After Safety Signal","url":"https://stock-news.laohu8.com/highlight/detail?id=2568299026","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568299026?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:39","pubTimestamp":1758314356,"startTime":"0","endTime":"0","summary":"Genfit  said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4085","VS","GNFT","GNFTF","BK4139"],"gpt_icon":0},{"id":"2568129181","title":"GENFIT Discontinues VS-01 Program in ACLF to Focus on UCD","url":"https://stock-news.laohu8.com/highlight/detail?id=2568129181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568129181?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:27","pubTimestamp":1758313661,"startTime":"0","endTime":"0","summary":"An announcement from Genfit SA ( ($GNFT) ) is now available. On September 19, 2025, GENFIT announced the discontinuation of its VS-01 program for A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-discontinues-vs-01-program-in-aclf-to-focus-on-ucd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-discontinues-vs-01-program-in-aclf-to-focus-on-ucd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4085","VS","BK4139","GNFTF"],"gpt_icon":0},{"id":"2544286992","title":"Press Release: GENFIT: June 17, 2025 Combined Shareholders Meeting Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2544286992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544286992?lang=en_us&edition=fundamental","pubTime":"2025-06-18 02:30","pubTimestamp":1750185000,"startTime":"0","endTime":"0","summary":"-- All resolutions recommended by the Board of Directors approved (quorum:. Lille , Cambridge , Zurich , June 17, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution ndeg28 which was rejected in accordance with the recommendations of the Board of Directors.The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website .This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as \"believe\", \"potential\", \"expect\", \"target\", \"may\", \"will\", \"should\", \"could\", \"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBC","NQmain","USA","GNFTF","GNFT","BK4022","CCA","BK4139","R","BK4232"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfit.com/","stockEarnings":[{"period":"1week","weight":-0.0739},{"period":"1month","weight":-0.1879},{"period":"3month","weight":-0.2811},{"period":"6month","weight":-0.4502},{"period":"1year","weight":-0.3426},{"period":"ytd","weight":-0.317}],"description":"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.","exchange":"PINK LIMITED","name":"Genfit","nameEN":"Genfit"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genfit(GNFTF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genfit,GNFTF,Genfit股票,Genfit股票老虎,Genfit股票老虎国际,Genfit行情,Genfit股票行情,Genfit股价,Genfit股市,Genfit股票价格,Genfit股票交易,Genfit股票购买,Genfit股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genfit(GNFTF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction